Working to Eradicate Gynecologic Cancers

Victoria L. Bae-Jump, MD, PhD

Associate Professor
University of North Carolina Lineberger Comprehensive Cancer Center
101 Manning Drive
Chapel Hill, NC
USA 27514


Biographical Sketch: Dr. Victoria Bae-Jump is an Assistant Professor in the Division of Gynecologic Oncology at the University of North Carolina at Chapel Hill (UNC-CH). She received her MD and PhD degree from Virginia Commonwealth University in Richmond, VA. Following this, she completed her Obstetrics and Gynecology Residency at UNC-CH in 2004 and her Fellowship in Gynecologic Oncology at UNC-CH in 2007. Dr. Bae-Jump is a translational cancer researcher at the UNC-CH Lineberger Comprehensive Cancer Center in the Clinical Research Program. Dr. Bae-Jump’s research focuses on understanding the interactions between cell signaling pathways implicated in ovarian and endometrial cancer pathogenesis as a means to target therapy for this disease, using cell culture, animal models and translational clinical trials. She is also interested in the impact obesity has on ovarian and endometrial cancer development and progression which may invariably dictate different risk reduction strategies and treatment options for this particularly high-risk patient population. In this pursuit, she has investigated many novel targeted therapies for the treatment of endometrial cancer, including mTOR inhibitors, arsenic, a human monoclonal antibody to the insulin growth factor-1 receptor (IGF-1R), soy, genistein, cox-2 inhibitors and most recently, metformin. Her pre-clinical work has led to several investigator-initiated clinical trials, including a pre-operative window study of metformin in obese endometrial cancer patients and a pilot study of meformin for the treatment of endometrial hyperplasia."

Papers:
8 - Focused Plenary Biological effects of metformin in a preoperative window clinical trial for endometrial cancer 64 - Scientific Plenary Preoperative quality of life in gynecologic oncology patients: a new predictor of operative risk? 79 - Focused Plenary Metformin and the risk of endometrial cancer: a population-based cohort study 82 - Featured Poster Gaps in adjuvant treatment in elderly endometrial cancer patients 95 - Featured Poster Do elderly women with endometrial cancer qualify for existing clinical trials? 104 -Featured Poster Endometrial cancer outcomes in diabetic women treated with metformin, statins, and aspirin 105 - Featured Poster Metformin has increased efficacy under obese conditions in a novel genetically engineered mouse model of serous ovarian cancer 121 - Featured Poster Differential gene expression was associated with increasing body mass index (BMI) among endometrial cancers from The Cancer Genome Atlas (TCGA) Project 124 - Featured Poster Obesity is associated with worse quality of life in women with gynecologic malignancies: an opportunity for improving patient-centered outcomes 276 - Poster Session A The HMG-CoA reductase inhibitor simvastatin exhibits antitumorigenic and antimetastatic effects in ovarian cancer 277 - Poster Session A Simvastatin, an HMG-CoA reductase inhibitor, exhibits antimetastatic and antitumorigenic effects in endometrial cancer 411 - Poster Session B Biguanides inhibit proliferation and decrease estrogen receptor expression in ovarian granulosa cell tumors 427 - Poster Session B Redefining the role of obesity, race and diabetes in Type I and Type II endometrial cancers: Potential targets for treatment beyond cancer itself 511 - Poster Session B The impact of outpatient versus inpatient referrals to hospice 527 - Poster Session B Location of Hospice Referral and its Impact on Subsequent ED visits Discussant Panelist